Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while JPMorgan Diversified Return International Eqty ETF trades at $77. The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | JPIN | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | — |
52-Week High | $76.78 | $77.00 |
52-Week Low | $44.34 | $64.96 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.
The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
